S&P 500   4,080.11
DOW   34,589.77
QQQ   293.36
The AP Interview: IMF head urges China to end mass lockdowns
Without Graphite, There Would Be ZERO EV Batteries! (Ad)
Santa Claus Rally? Here’s What Needs to Happen
25 Ways to Improve Your Financial Situation in 1 Hour
Without Graphite, There Would Be ZERO EV Batteries! (Ad)
Cosmos Holdings May be a Long-Term Buy with Short-Term Risk
Dark Clouds Are Gathering For Cloud Stocks 
Without Graphite, There Would Be ZERO EV Batteries! (Ad)
An inflation gauge closely tracked by the Federal Reserve slowed to a still-high 6% in October
Will Easing Of Covid Rules Slash Risk For Chinese EV Maker NIO?
S&P 500   4,080.11
DOW   34,589.77
QQQ   293.36
The AP Interview: IMF head urges China to end mass lockdowns
Without Graphite, There Would Be ZERO EV Batteries! (Ad)
Santa Claus Rally? Here’s What Needs to Happen
25 Ways to Improve Your Financial Situation in 1 Hour
Without Graphite, There Would Be ZERO EV Batteries! (Ad)
Cosmos Holdings May be a Long-Term Buy with Short-Term Risk
Dark Clouds Are Gathering For Cloud Stocks 
Without Graphite, There Would Be ZERO EV Batteries! (Ad)
An inflation gauge closely tracked by the Federal Reserve slowed to a still-high 6% in October
Will Easing Of Covid Rules Slash Risk For Chinese EV Maker NIO?
S&P 500   4,080.11
DOW   34,589.77
QQQ   293.36
The AP Interview: IMF head urges China to end mass lockdowns
Without Graphite, There Would Be ZERO EV Batteries! (Ad)
Santa Claus Rally? Here’s What Needs to Happen
25 Ways to Improve Your Financial Situation in 1 Hour
Without Graphite, There Would Be ZERO EV Batteries! (Ad)
Cosmos Holdings May be a Long-Term Buy with Short-Term Risk
Dark Clouds Are Gathering For Cloud Stocks 
Without Graphite, There Would Be ZERO EV Batteries! (Ad)
An inflation gauge closely tracked by the Federal Reserve slowed to a still-high 6% in October
Will Easing Of Covid Rules Slash Risk For Chinese EV Maker NIO?
S&P 500   4,080.11
DOW   34,589.77
QQQ   293.36
The AP Interview: IMF head urges China to end mass lockdowns
Without Graphite, There Would Be ZERO EV Batteries! (Ad)
Santa Claus Rally? Here’s What Needs to Happen
25 Ways to Improve Your Financial Situation in 1 Hour
Without Graphite, There Would Be ZERO EV Batteries! (Ad)
Cosmos Holdings May be a Long-Term Buy with Short-Term Risk
Dark Clouds Are Gathering For Cloud Stocks 
Without Graphite, There Would Be ZERO EV Batteries! (Ad)
An inflation gauge closely tracked by the Federal Reserve slowed to a still-high 6% in October
Will Easing Of Covid Rules Slash Risk For Chinese EV Maker NIO?

Adverum Biotechnologies - ADVM News Today

$0.67
-0.01 (-1.47%)
(As of 11/30/2022 12:00 AM ET)
Add
Compare
Today's Range
$0.65
$0.70
50-Day Range
$0.64
$1.03
52-Week Range
$0.63
$2.04
Volume
688,370 shs
Average Volume
736,099 shs
Market Capitalization
$66.81 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$3.00
Get Adverum Biotechnologies News Delivered to You Automatically

Sign up to receive the latest news and ratings for ADVM and its competitors with MarketBeat's FREE daily newsletter.



ADVM Media Mentions By Week

ADVM Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

ADVM
News Sentiment

1.89

0.71

Average
Medical
News Sentiment

ADVM News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

ADVM Articles
This Week

1

1

ADVM Articles
Average Week

SourceHeadline
finanznachrichten.de logoAdverum Biotechnologies, Inc.: Adverum Biotechnologies Reports Third Quarter 2022 Financial Results
finanznachrichten.de - November 12 at 7:52 AM
finance.yahoo.com logoAdverum Biotechnologies Reports Third Quarter 2022 Financial Results
finance.yahoo.com - November 10 at 4:19 PM
finance.yahoo.com logoAdverum Biotechnologies Presents Positive End of Study Results from the OPTIC Trial in Wet AMD Including Two-Year Outcomes Following a Single Intravitreal Injection of Ixo-vec (ADVM-022)
finance.yahoo.com - November 4 at 7:12 PM
finance.yahoo.com logoAdverum Biotechnologies Announces Upcoming Data Presentation at The Retina Society Annual Meeting
finance.yahoo.com - October 27 at 6:09 PM
finance.yahoo.com logoAdverum Biotechnologies Presents Anatomical Improvements in Intraretinal and Subretinal Fluid After a Single IVT Injection of Ixo-vec (ADVM-022) in the OPTIC Study in Wet AMD
finance.yahoo.com - September 30 at 6:59 PM
finance.yahoo.com logoAdverum Biotechnologies to Participate in the Chardan 6th Annual Genetic Medicines Conference
finance.yahoo.com - September 27 at 6:13 PM
finance.yahoo.com logoAdverum Biotechnologies to Participate in the Jefferies Cell and Genetic Medicine Summit
finance.yahoo.com - September 23 at 8:21 PM
finance.yahoo.com logoHere's Why We're Watching Adverum Biotechnologies' (NASDAQ:ADVM) Cash Burn Situation
finance.yahoo.com - September 23 at 3:17 PM
finance.yahoo.com logoAdverum Biotechnologies Announces Upcoming Data Presentation at AAO 2022
finance.yahoo.com - September 23 at 10:17 AM
finance.yahoo.com logoAdverum (ADVM) Doses First Patient in the Mid-Stage wAMD Study
finance.yahoo.com - September 15 at 11:21 PM
finance.yahoo.com logoAdverum Biotechnologies Announces First Subject Dosed with Ixo-vec in the Phase 2 LUNA Trial for the Treatment of Wet Age-Related Macular Degeneration
finance.yahoo.com - September 14 at 9:56 AM
finance.yahoo.com logoAdverum Biotechnologies to Participate in the H.C. Wainwright 24th Annual Global Investment Conference
finance.yahoo.com - September 8 at 8:42 PM
finance.yahoo.com logoAdverum to Present at the Inaugural Gilmartin Group Emerging Growth Company Showcase
finance.yahoo.com - August 26 at 5:01 PM
finance.yahoo.com logoAdverum Biotechnologies to Participate in the 2nd Annual H.C. Wainwright Ophthalmology Virtual Conference
finance.yahoo.com - August 10 at 8:49 PM
finance.yahoo.com logoQuite a few insiders invested in Adverum Biotechnologies, Inc. (NASDAQ:ADVM) last year which is positive news for shareholders
finance.yahoo.com - July 25 at 11:04 AM
finance.yahoo.com logoAdverum Posts New Data From Wet AMD Gene Therapy Trial
finance.yahoo.com - July 15 at 1:55 PM
finance.yahoo.com logoAdverum Biotechnologies Presents Best-Corrected Visual Acuity and Central Subfield Thickness Analyses After a Single IVT Injection of ADVM-022 (Ixo-vec) in the OPTIC Study in Wet AMD
finance.yahoo.com - July 15 at 8:54 AM
finance.yahoo.com logoAdverum Biotechnologies Announces Upcoming Data Presentation at ASRS 2022
finance.yahoo.com - July 8 at 12:20 PM
bizjournals.com logoA Redwood City gene therapy company is cutting 78 jobs as it jump-starts a program to treat a common cause of blindness
bizjournals.com - July 7 at 9:19 PM
msn.com logoThe Daily Biotech Pulse: Merck's Seagen Buyout Advances, Adverum Restructures, Pharmacists Get OK To Prescribe Pfizer COVID-19 Pill
msn.com - July 7 at 4:16 PM
finance.yahoo.com logoAdverum Biotechnologies Cuts Workforce, Prioritizes ADVM-022
finance.yahoo.com - July 7 at 4:16 PM
finance.yahoo.com logoAdverum (ADVM) Completes IND Amendment for Gene Therapy Study
finance.yahoo.com - July 7 at 4:16 PM
finance.yahoo.com logoAdverum Biotechnologies Completes IND Amendment and Prepares to Initiate the Phase 2 LUNA Trial of ADVM-022 in Wet AMD
finance.yahoo.com - July 6 at 4:13 PM
finance.yahoo.com logoAdverum Biotechnologies Granted Priority Medicines (PRIME) Designation by European Medicines Agency for ADVM-022 in Wet AMD
finance.yahoo.com - June 24 at 9:15 AM
finance.yahoo.com logoAdverum Biotechnologies Presents Three-Year Aflibercept Protein Expression and Improvement in Anatomic Outcomes After a Single IVT Injection of ADVM-022 in the OPTIC Study in Wet AMD
finance.yahoo.com - June 9 at 9:14 AM
finance.yahoo.com logoAdverum Biotechnologies Announces New Data at the Macula Society’s 2022 Annual Meeting
finance.yahoo.com - June 2 at 5:09 PM
finance.yahoo.com logoAdverum Biotechnologies Presents Research Pipeline Data Supporting Utility of its Proprietary Platform and AAV.7m8 Capsid in Ocular Gene Therapy
finance.yahoo.com - May 19 at 8:45 AM
finance.yahoo.com logoAdverum Presents Data at ASGCT Further Supporting Phase 2 Development Plans for ADVM-022
finance.yahoo.com - May 17 at 8:56 PM
seekingalpha.com logoAdverum Biotechnologies GAAP EPS of -$0.38 misses by $0.07
seekingalpha.com - May 13 at 3:03 AM
finance.yahoo.com logoHow Much Of Adverum Biotechnologies, Inc. (NASDAQ:ADVM) Do Institutions Own?
finance.yahoo.com - May 11 at 7:32 PM
morningstar.com logoAdverum Biotechnologies Announces Upcoming Data Presentations at ASGCT 2022 | Morningstar
morningstar.com - May 4 at 9:34 PM
finance.yahoo.com logoAdverum Biotechnologies Announces Upcoming Data Presentations at ASGCT 2022
finance.yahoo.com - May 2 at 4:44 PM
finance.yahoo.com logoAdverum Bio Posts Additional Efficacy, Safety Data From ADVM-022 Gene Therapy In Wet AMD
finance.yahoo.com - May 2 at 11:44 AM
nasdaq.com logoThursday 4/21 Insider Buying Report: TPL, ADVM
nasdaq.com - April 21 at 6:30 PM
finance.yahoo.com logoAdverum Moves Forward With IND Amendment For ADVM-022 Phase 2 Trial In Wet AMD
finance.yahoo.com - April 7 at 12:57 PM
seekingalpha.com logoAdverum gets FDA feedback on mid-stage trial for Wet AMD candidate
seekingalpha.com - April 6 at 4:56 PM
finance.yahoo.com logoAdverum Biotechnologies Proceeds with IND Amendment for ADVM-022 Phase 2 Trial in Wet AMD After Receiving Requested Type C Meeting Feedback from the FDA
finance.yahoo.com - April 6 at 4:56 PM
seekingalpha.com logoAdverum Biotechnologies GAAP EPS of -$0.35 misses by $0.01
seekingalpha.com - March 29 at 6:20 PM
finance.yahoo.com logoAdverum Biotechnologies Reports Fourth Quarter and Full Year 2021 Financial Results
finance.yahoo.com - March 29 at 6:20 PM
nasdaq.com logoShould You Buy Adverum Biotechnologies (ADVM) Ahead of Earnings?
nasdaq.com - March 2 at 2:46 PM
finance.yahoo.com logoAdverum Biotechnologies to Participate in the 42nd Annual Cowen Healthcare Conference
finance.yahoo.com - February 28 at 10:22 AM
finance.yahoo.com logoInsiders who bought in the last 12 months lose an additional US$367k as Adverum Biotechnologies, Inc. (NASDAQ:ADVM) drops to US$136m
finance.yahoo.com - February 15 at 7:34 AM
seekingalpha.com logoAdverum Biotechnologies names new CMO
seekingalpha.com - February 7 at 8:04 PM
finance.yahoo.com logoAdverum Biotechnologies Appoints Richard Beckman M.D. as Chief Medical Officer
finance.yahoo.com - February 7 at 8:04 PM
finance.yahoo.com logoAdverum Biotechnologies Appoints Star Seyedkazemi, Pharm.D. as Chief Development Officer
finance.yahoo.com - January 6 at 6:36 PM
finance.yahoo.com logoAdverum Biotechnologies Granted Orphan Drug Designation by FDA for Gene Therapy Candidate in Preclinical Development for the Treatment of Blue Cone Monochromacy
finance.yahoo.com - January 4 at 12:32 PM
nasdaq.com logoShareholders in Adverum Biotechnologies (NASDAQ:ADVM) are in the red if they invested a year ago
nasdaq.com - January 3 at 8:02 AM
finance.yahoo.com logoAdverum Biotechnologies (NASDAQ:ADVM) investors are sitting on a loss of 84% if they invested a year ago
finance.yahoo.com - January 1 at 8:12 AM
finance.yahoo.com logoAdverum Outlines Development Plan For ADVM-022 Gene Therapy In Wet AMD
finance.yahoo.com - December 21 at 5:50 PM
benzinga.com logoAdverum Biotechnologies Says Finalizing 2-Dose Study Design For Phase 2 Trial Of ADVN-022 In Wet AMD With Intention To Dose First Patient In Q3 2022
benzinga.com - December 21 at 12:49 PM
Get Adverum Biotechnologies News Delivered to You Automatically

Sign up to receive the latest news and ratings for ADVM and its competitors with MarketBeat's FREE daily newsletter.

This page (NASDAQ:ADVM) was last updated on 12/1/2022 by MarketBeat.com Staff